Jacobs Levy Equity Management’s TRACON Pharmaceuticals TCON Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q1
– Sell
-491
Closed -$62K – 1061
2018
Q4
$62K Buy
491
+127
+35% +$34.5K ﹤0.01% 952
2018
Q3
$149K Sell
364
-47
-11% -$21.8K ﹤0.01% 951
2018
Q2
$222K Sell
411
-346
-46% -$184K ﹤0.01% 936
2018
Q1
$348K Buy
757
+323
+74% +$176K 0.01% 839
2017
Q4
$291K Buy
+434
New +$262K 0.01% 850
2017
Q3
– Sell
-258
Closed -$124K – 1028
2017
Q2
$124K Buy
258
+170
+193% +$104K ﹤0.01% 885
2017
Q1
$66K Sell
88
-56
-39% -$50.2K ﹤0.01% 884
2016
Q4
$141K Sell
144
-36
-20% -$41.1K ﹤0.01% 864
2016
Q3
$240K Sell
180
-6
-3% -$6.76K ﹤0.01% 860
2016
Q2
$162K Buy
+186
New +$246K ﹤0.01% 1045

Other funds holding TCON

Jacobs Levy Equity Management's TCON Position: Q1 2019 in Review

Jacobs Levy Equity Management sold out of TRACON Pharmaceuticals (TCON) in Q1 2019, closing a stake of 491 shares — an estimated $62K sold.

Jacobs Levy Equity Management first reported a position in TCON in Q2 2016 and held it in 10 quarters. The position peaked at $348K in Q1 2018. 24 funds tracked by Wall St. Rank hold TCON as of Q1 2019.

  • Jacobs Levy Equity Management reported no remaining TRACON Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 491 TRACON Pharmaceuticals shares in Q1 2019, an estimated $62K.
  • Jacobs Levy Equity Management first reported a position in TRACON Pharmaceuticals in Q2 2016 and held it in 10 quarters.
  • Jacobs Levy Equity Management's TRACON Pharmaceuticals position peaked at $348K in Q1 2018.
  • 24 funds tracked by Wall St. Rank held TRACON Pharmaceuticals as of Q1 2019.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2019, filed 14 May 2019.